Aszpart inzulin a diabetológiai gyakorlatban

Translated title of the contribution: Insulin aspart in the clinical practice

Research output: Contribution to journalArticle

Abstract

Insulin aspart (B28 Asp-insulin), which is produced by recombinant DNA technology, is a fast-acting insulin analogue. Due to the aspartate for proline substitution at position 28 of the B-chain, the insulin molecule's tendency for self-association is diminished, therefore, insulin aspart rapidly dissociates into dimeric and monomeric forms and absorbs quickly and easily after subcutaneous administration. Compared to human regular insulin, insulin aspart has a faster onset of activity, a higher plasma peak and a shorter duration of action. Overall, the pharmacokinetic profile of insulin aspart better mimics the physiological postprandial insulin secretion. Therefore, insulin aspart can be used for prandial insulin substitution in order to decrease postprandial blood glucose excursion. It should be administered immediately before meals, but some observations suggest that it can also be used after finishing meal. This allows a more flexible lifestyle for patients. Insulin aspart can be used in both type 1 and type 2 diabetes. Compared to regular human insulin, a moderate decrease in the HbA1c values and fewer nocturnal hypoglycaemic events are expected from insulin aspart use. Insulin aspart is appropriate for pump treatment as well. It has recently been approved for use in pregnancy, whereas for children and adolescents the expected benefits should be weighed against the more modest clinical experience available. Similarly to other insulin analogues, results of long-term clinical investigations with insulin aspart with regard to the development of complications are not yet available.

Original languageHungarian
Pages (from-to)941-947
Number of pages7
JournalLege Artis Medicinae
Volume16
Issue number11
Publication statusPublished - Nov 2006

Fingerprint

Insulin Aspart
Insulin
Insulin, Regular, Human
Meals
Recombinant DNA
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Proline
Aspartic Acid
Type 2 Diabetes Mellitus
Blood Glucose
Life Style
Pharmacokinetics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aszpart inzulin a diabetológiai gyakorlatban. / Jermendy, G.

In: Lege Artis Medicinae, Vol. 16, No. 11, 11.2006, p. 941-947.

Research output: Contribution to journalArticle

@article{2826c92714874cf6a6caa11b8bfb96e8,
title = "Aszpart inzulin a diabetol{\'o}giai gyakorlatban",
abstract = "Insulin aspart (B28 Asp-insulin), which is produced by recombinant DNA technology, is a fast-acting insulin analogue. Due to the aspartate for proline substitution at position 28 of the B-chain, the insulin molecule's tendency for self-association is diminished, therefore, insulin aspart rapidly dissociates into dimeric and monomeric forms and absorbs quickly and easily after subcutaneous administration. Compared to human regular insulin, insulin aspart has a faster onset of activity, a higher plasma peak and a shorter duration of action. Overall, the pharmacokinetic profile of insulin aspart better mimics the physiological postprandial insulin secretion. Therefore, insulin aspart can be used for prandial insulin substitution in order to decrease postprandial blood glucose excursion. It should be administered immediately before meals, but some observations suggest that it can also be used after finishing meal. This allows a more flexible lifestyle for patients. Insulin aspart can be used in both type 1 and type 2 diabetes. Compared to regular human insulin, a moderate decrease in the HbA1c values and fewer nocturnal hypoglycaemic events are expected from insulin aspart use. Insulin aspart is appropriate for pump treatment as well. It has recently been approved for use in pregnancy, whereas for children and adolescents the expected benefits should be weighed against the more modest clinical experience available. Similarly to other insulin analogues, results of long-term clinical investigations with insulin aspart with regard to the development of complications are not yet available.",
keywords = "Hypoglycaemia, Insulin analogues, Insulin aspart, Insulin treatment, Postprandial hyperglycaemia",
author = "G. Jermendy",
year = "2006",
month = "11",
language = "Hungarian",
volume = "16",
pages = "941--947",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - Aszpart inzulin a diabetológiai gyakorlatban

AU - Jermendy, G.

PY - 2006/11

Y1 - 2006/11

N2 - Insulin aspart (B28 Asp-insulin), which is produced by recombinant DNA technology, is a fast-acting insulin analogue. Due to the aspartate for proline substitution at position 28 of the B-chain, the insulin molecule's tendency for self-association is diminished, therefore, insulin aspart rapidly dissociates into dimeric and monomeric forms and absorbs quickly and easily after subcutaneous administration. Compared to human regular insulin, insulin aspart has a faster onset of activity, a higher plasma peak and a shorter duration of action. Overall, the pharmacokinetic profile of insulin aspart better mimics the physiological postprandial insulin secretion. Therefore, insulin aspart can be used for prandial insulin substitution in order to decrease postprandial blood glucose excursion. It should be administered immediately before meals, but some observations suggest that it can also be used after finishing meal. This allows a more flexible lifestyle for patients. Insulin aspart can be used in both type 1 and type 2 diabetes. Compared to regular human insulin, a moderate decrease in the HbA1c values and fewer nocturnal hypoglycaemic events are expected from insulin aspart use. Insulin aspart is appropriate for pump treatment as well. It has recently been approved for use in pregnancy, whereas for children and adolescents the expected benefits should be weighed against the more modest clinical experience available. Similarly to other insulin analogues, results of long-term clinical investigations with insulin aspart with regard to the development of complications are not yet available.

AB - Insulin aspart (B28 Asp-insulin), which is produced by recombinant DNA technology, is a fast-acting insulin analogue. Due to the aspartate for proline substitution at position 28 of the B-chain, the insulin molecule's tendency for self-association is diminished, therefore, insulin aspart rapidly dissociates into dimeric and monomeric forms and absorbs quickly and easily after subcutaneous administration. Compared to human regular insulin, insulin aspart has a faster onset of activity, a higher plasma peak and a shorter duration of action. Overall, the pharmacokinetic profile of insulin aspart better mimics the physiological postprandial insulin secretion. Therefore, insulin aspart can be used for prandial insulin substitution in order to decrease postprandial blood glucose excursion. It should be administered immediately before meals, but some observations suggest that it can also be used after finishing meal. This allows a more flexible lifestyle for patients. Insulin aspart can be used in both type 1 and type 2 diabetes. Compared to regular human insulin, a moderate decrease in the HbA1c values and fewer nocturnal hypoglycaemic events are expected from insulin aspart use. Insulin aspart is appropriate for pump treatment as well. It has recently been approved for use in pregnancy, whereas for children and adolescents the expected benefits should be weighed against the more modest clinical experience available. Similarly to other insulin analogues, results of long-term clinical investigations with insulin aspart with regard to the development of complications are not yet available.

KW - Hypoglycaemia

KW - Insulin analogues

KW - Insulin aspart

KW - Insulin treatment

KW - Postprandial hyperglycaemia

UR - http://www.scopus.com/inward/record.url?scp=33845274557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845274557&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33845274557

VL - 16

SP - 941

EP - 947

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -